title: Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.
abstract: We have recently reported that the administration of AM404, an inhibitor of the endocannabinoid re-uptake process, which also has affinity for the vanilloid VR1 receptors, is able to reduce hyperkinesia, and causes recovery from neurochemical deficits, in a rat model of Huntington's disease (HD) generated by bilateral intrastriatal injections of 3-nitropropionic acid (3NP). In the present study, we wanted to explore the mechanism(s) by which AM404 produces its antihyperkinetic effect in 3NP-lesioned rats by employing several experimental approaches. First, we tried to block the effects of AM404 with selective antagonists for the CB1 or VR1 receptors, i.e. SR141716A and capsazepine, respectively. We found that the reduction caused by AM404 of the increased ambulation exhibited by 3NP-lesioned rats in the open-field test was reversed when the animals had been pre-treated with capsazepine but not with SR141716A, thus suggesting a major role of VR1 receptors in the antihyperkinetic effects of AM404. However, despite the lack of behavioral effects of the CB1 receptor antagonist, the pretreatment with this compound abolished the recovery of neurochemical [gamma-aminobutyric acid (GABA) and dopamine] deficits in the caudate- putamen caused by AM404, as also did capsazepine. In a second group of studies, we wanted to explore the potential antihyperkinetic effects of various compounds which, compared to AM404, exhibit more selectivity for either the endovanilloid or the endocannabinoid systems. First, we tested VDM11 or AM374, two selective inhibitors or the endocannabinoid re-uptake or hydrolysis, respectively. Both compounds were mostly unable to reduce hyperkinesia in 3NP-lesioned rats, although VDM11 produced a certain motor depression, and AM374 exhibited a trend to stimulate ambulation, in control rats. We also tested the effects of selective direct agonists for VR1 (capsaicin) or CB1 (CP55,940) receptors. Capsaicin exhibited a strong antihyperkinetic activity and, moreover, was able to attenuate the reductions in dopamine and GABA transmission provoked by the 3NP lesion, whereas CP55,940 had also antihyperkinetic activity but was unable to cause recovery of either dopamine or GABA deficits in the basal ganglia. In summary, our data indicate a major role for VR1 receptors, as compared to CB1 receptors, in the antihyperkinetic effects and the recovery of neurochemical deficits caused in 3NP-lesioned rats by compounds that activate both CB1 and VR1 receptors, either directly or via manipulation of the levels of endogenous agonists.
authors.affiliation: Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad Complutense, 28040-Madrid, Spain.
authors.forename: Isabel
authors.initials: I
authors.lastname: Lastres-Becker
authors.forename: Rosario
authors.initials: R
authors.lastname: de Miguel
authors.forename: Luciano
authors.initials: L
authors.lastname: De Petrocellis
authors.forename: Alexandros
authors.initials: A
authors.lastname: Makriyannis
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Marzo
authors.forename: Javier
authors.initials: J
authors.lastname: Fernández-Ruiz
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D021542:Amino Acids, Neutral / Q000494:pharmacology; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D001479:Basal Ganglia / Q000187:drug effects; D063385:Cannabinoid Receptor Modulators; D002211:Capsaicin / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects; D003511:Cyclohexanols / Q000494:pharmacology; D004195:Disease Models, Animal; D004298:Dopamine / Q000378:metabolism; D063388:Endocannabinoids; D006816:Huntington Disease / Q000139:chemically induced / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D006948:Hyperkinesis / Q000188:drug therapy*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009574:Nitro Compounds; D010168:Palmitates / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D011422:Propionates; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000077285:Rimonabant; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: C104963:AM 374; D021542:Amino Acids, Neutral; D001095:Arachidonic Acids; D063385:Cannabinoid Receptor Modulators; D003511:Cyclohexanols; D063388:Endocannabinoids; C462953:N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide; D009574:Nitro Compounds; D010168:Palmitates; D010880:Piperidines; D011422:Propionates; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D015102:3,4-Dihydroxyphenylacetic Acid; D005680:gamma-Aminobutyric Acid; C013809:5-aminovaleric acid; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; C015392:3-nitropropionic acid; D000077285:Rimonabant; D002211:Capsaicin; D004298:Dopamine; C107594:N-(4-hydroxyphenyl)arachidonylamide